Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘mTOR inhibitors’

Just can’t get enough

Gone Fishing!

The dawn of the 1980s represented a much more optimistic future than what it eventually turned out to be – will we see the same trend evolve with the seemingly myriad of attempts to box in certain cancer targets?

In some ways this has turned into a bit of a fishing expedition in several ways:

  • Uncovering mechanisms of resistance
  • Finding rational combinations with a decent therapeutic window
  • Developing next generation agents to address the limitations of the earlier versions

If we want to see success in the clinic then what might this look like in the next round of trials and who are the companies active in developing them?

It turns out there are a few surprises in store…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

The changing face of the SCCHN landscape

It’s been very clear for over four years now that combinations were going to be necessary if we want to a larger number of deeper and more durable responses than can attained with monotherapy.  Gradually, we are starting to see early and very preliminary readouts with some of the trials in progress.

We are also learning very quickly that it’s going to be a case of #notalltumours and #notallsubsets.

ASCO 2016 Posters 2

Another very busy poster session at #ASCO16!

By this, I mean we obviously can’t take a one-combination-fits-all approach for all tumour types.

We need to be able to classify patients into more homogenous subsets and then devise different combinations or even sequences that address the underlying biology of both the cancer itself and also the tumour microenvironment.  That’s going to take a while to sort out, perhaps even years.

Let’s not forget though that in the meantime, we can gather information quite a few clues both preclinically, as well as from initial clinical studies.  Sometimes, after all, we even learn more from negative trials than positive ones. This is an area that is ripe for combinations with traditional targeted therapies, the question is which ones are promising and why?

We took a look at the landscape in SCCH&N and how this might evolve over time in the medium term, with future opportunities, that can be explored in rational combination approaches.

To learn more, subscribers can log-in or you can sign-up to join the ever-growing BSB club.

This content is restricted to subscribers

error: Content is protected !!